Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach
Background The challenges that remain in the treatment of solid tumors with chimeric antigen receptor (CAR)-T cells include limited solid tumor-specific targets and poor CAR-T cell expansion and function due to limited availability of solid tumor antigens outside the tumor microenvironment. Prostate...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/5/e011238.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849387124389838848 |
|---|---|
| author | Wei Ding Xi Huang Zhiyuan Cao Chengfei Pu Xianyang Jiang Xiaogang Shen Zhao Wu Lei Xiao Beibei Jia Guiting Han Wensheng Wang Zhipeng Huang Victor X Lu Le Tian |
| author_facet | Wei Ding Xi Huang Zhiyuan Cao Chengfei Pu Xianyang Jiang Xiaogang Shen Zhao Wu Lei Xiao Beibei Jia Guiting Han Wensheng Wang Zhipeng Huang Victor X Lu Le Tian |
| author_sort | Wei Ding |
| collection | DOAJ |
| description | Background The challenges that remain in the treatment of solid tumors with chimeric antigen receptor (CAR)-T cells include limited solid tumor-specific targets and poor CAR-T cell expansion and function due to limited availability of solid tumor antigens outside the tumor microenvironment. Prostate cancer is the second most common cancer among men worldwide. Current CAR-T therapies for prostate cancer lack specific targets, posing safety risks. To overcome these problems, we identified prostatic acid phosphatase (PAP, also known as ACPP or ACP3) as a feasible CAR-T target for prostate cancer and developed CoupledCAR, a novel approach for expanding tumor-targeting CAR-T cells without tumor antigens.Methods We analyzed the expression of PAP from The Cancer Genome Atlas database and validated its expression in normal and cancer tissues through immunohistochemistry staining. To generate anti-PAP specific antibodies, we screened the human single-chain antibody library using transmembrane PAP-His antigen and selected antibodies based on their binding ability and specificity. We constructed PAP-targeted CAR and evaluated their antitumor efficacy both in vitro and in vivo. We validated the function of PAP CoupledCAR in both in vitro and in vivo experiments, and further analyzed its mechanism using single-cell RNA sequencing (scRNA-Seq).Results PAP was specifically expressed in prostate epithelial and prostate cancer cells, with no expression in other tissues. Seven single-chain variable fragments were screened from the human single-chain antibody library, with S5D1 showing the highest binding ability for the PAP. PAP CAR-T cells demonstrated strong antitumor efficacy both in vitro and in vivo. Furthermore, the CoupledCAR system significantly expanded PAP CAR-T cells, promoting memory-like status, reducing exhaustion, and enhancing their antitumor efficacy. The scRNA-Seq demonstrated that the expansion of PAP CAR-T cells in the CoupledCAR system is mediated by costimulatory signals and cytokine signals, rather than T-cell receptor signals.Conclusions Our study is the first to demonstrate that PAP is a specific target for CAR-T therapy in prostate cancer, both in vitro and in vivo. We developed the CoupledCAR platform technology for solid tumor CAR-T cell therapy, enabling the expansion of tumor-targeting CAR-T cells without requiring tumor antigens and thereby enhancing their functionality against solid tumors. |
| format | Article |
| id | doaj-art-1ca81e4874804fe0b73253da53b64c55 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-1ca81e4874804fe0b73253da53b64c552025-08-20T03:55:22ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-05-0113510.1136/jitc-2024-011238Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approachWei Ding0Xi Huang1Zhiyuan Cao2Chengfei Pu3Xianyang Jiang4Xiaogang Shen5Zhao Wu6Lei Xiao7Beibei Jia8Guiting Han9Wensheng Wang10Zhipeng Huang11Victor X Lu12Le Tian13Innovative Cellular Therapeutics, Shanghai, ChinaInnovative Cellular Therapeutics, Shanghai, ChinaInnovative Cellular Therapeutics, Shanghai, ChinaInnovative Cellular Therapeutics, Shanghai, ChinaInnovative Cellular Therapeutics, Shanghai, ChinaInnovative Cellular Therapeutics, Shanghai, ChinaInnovative Cellular Therapeutics, Shanghai, ChinaInnovative Cellular Therapeutics Holdings Limited, Rockville, Maryland, USAInnovative Cellular Therapeutics, Shanghai, ChinaInnovative Cellular Therapeutics, Shanghai, ChinaInnovative Cellular Therapeutics, Shanghai, ChinaInnovative Cellular Therapeutics, Shanghai, ChinaInnovative Cellular Therapeutics Holdings Limited, Rockville, Maryland, USAInnovative Cellular Therapeutics Holdings Limited, Rockville, Maryland, USABackground The challenges that remain in the treatment of solid tumors with chimeric antigen receptor (CAR)-T cells include limited solid tumor-specific targets and poor CAR-T cell expansion and function due to limited availability of solid tumor antigens outside the tumor microenvironment. Prostate cancer is the second most common cancer among men worldwide. Current CAR-T therapies for prostate cancer lack specific targets, posing safety risks. To overcome these problems, we identified prostatic acid phosphatase (PAP, also known as ACPP or ACP3) as a feasible CAR-T target for prostate cancer and developed CoupledCAR, a novel approach for expanding tumor-targeting CAR-T cells without tumor antigens.Methods We analyzed the expression of PAP from The Cancer Genome Atlas database and validated its expression in normal and cancer tissues through immunohistochemistry staining. To generate anti-PAP specific antibodies, we screened the human single-chain antibody library using transmembrane PAP-His antigen and selected antibodies based on their binding ability and specificity. We constructed PAP-targeted CAR and evaluated their antitumor efficacy both in vitro and in vivo. We validated the function of PAP CoupledCAR in both in vitro and in vivo experiments, and further analyzed its mechanism using single-cell RNA sequencing (scRNA-Seq).Results PAP was specifically expressed in prostate epithelial and prostate cancer cells, with no expression in other tissues. Seven single-chain variable fragments were screened from the human single-chain antibody library, with S5D1 showing the highest binding ability for the PAP. PAP CAR-T cells demonstrated strong antitumor efficacy both in vitro and in vivo. Furthermore, the CoupledCAR system significantly expanded PAP CAR-T cells, promoting memory-like status, reducing exhaustion, and enhancing their antitumor efficacy. The scRNA-Seq demonstrated that the expansion of PAP CAR-T cells in the CoupledCAR system is mediated by costimulatory signals and cytokine signals, rather than T-cell receptor signals.Conclusions Our study is the first to demonstrate that PAP is a specific target for CAR-T therapy in prostate cancer, both in vitro and in vivo. We developed the CoupledCAR platform technology for solid tumor CAR-T cell therapy, enabling the expansion of tumor-targeting CAR-T cells without requiring tumor antigens and thereby enhancing their functionality against solid tumors.https://jitc.bmj.com/content/13/5/e011238.full |
| spellingShingle | Wei Ding Xi Huang Zhiyuan Cao Chengfei Pu Xianyang Jiang Xiaogang Shen Zhao Wu Lei Xiao Beibei Jia Guiting Han Wensheng Wang Zhipeng Huang Victor X Lu Le Tian Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach Journal for ImmunoTherapy of Cancer |
| title | Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach |
| title_full | Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach |
| title_fullStr | Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach |
| title_full_unstemmed | Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach |
| title_short | Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach |
| title_sort | novel pap targeted car t therapy enhances antitumor efficacy through coupledcar approach |
| url | https://jitc.bmj.com/content/13/5/e011238.full |
| work_keys_str_mv | AT weiding novelpaptargetedcarttherapyenhancesantitumorefficacythroughcoupledcarapproach AT xihuang novelpaptargetedcarttherapyenhancesantitumorefficacythroughcoupledcarapproach AT zhiyuancao novelpaptargetedcarttherapyenhancesantitumorefficacythroughcoupledcarapproach AT chengfeipu novelpaptargetedcarttherapyenhancesantitumorefficacythroughcoupledcarapproach AT xianyangjiang novelpaptargetedcarttherapyenhancesantitumorefficacythroughcoupledcarapproach AT xiaogangshen novelpaptargetedcarttherapyenhancesantitumorefficacythroughcoupledcarapproach AT zhaowu novelpaptargetedcarttherapyenhancesantitumorefficacythroughcoupledcarapproach AT leixiao novelpaptargetedcarttherapyenhancesantitumorefficacythroughcoupledcarapproach AT beibeijia novelpaptargetedcarttherapyenhancesantitumorefficacythroughcoupledcarapproach AT guitinghan novelpaptargetedcarttherapyenhancesantitumorefficacythroughcoupledcarapproach AT wenshengwang novelpaptargetedcarttherapyenhancesantitumorefficacythroughcoupledcarapproach AT zhipenghuang novelpaptargetedcarttherapyenhancesantitumorefficacythroughcoupledcarapproach AT victorxlu novelpaptargetedcarttherapyenhancesantitumorefficacythroughcoupledcarapproach AT letian novelpaptargetedcarttherapyenhancesantitumorefficacythroughcoupledcarapproach |